Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

Open Access 01-09-2015 | Research Article

Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma

Authors: Hong-Fang Duan, Xiao-Qing Li, Hong-Yi Hu, Yu-Chi Li, Zhi Cai, Xue-Shuang Mei, Peng Yu, Li-Ping Nie, Wei Zhang, Zhen-Dong Yu, Guo-Hui Nie

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Nasopharyngeal carcinoma has very high incidence and high mortality worldwide. MiRNA is related to the tumorigenesis and metastasis of a variety of tumors. In the present study, we verify that the expression of miR-494 in NPC tissues and NPC-derived cells was down-regulated, respectively. The proliferation, colony formation, migration, and invasion of NPC-derived cells were suppressed, while the cell apoptosis was promoted, when miR-494 was over-expressed in these cells. GALNT7 and CDK16 were confirmed to be the direct targets of miR-494. These results suggested that miR-494 play an inhibitory role in the tumorigenesis of NPC.
Literature
1.
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008;99:1311–8.CrossRefPubMed
4.
Kim Y, Kim B, Jung S, Jung SL, Lee YS, Kim MS, et al. Radiation therapy combined with (or without) cisplatin-based chemotherapy for patients with nasopharyngeal cancer: 15-years experience of a single institution in Korea. Cancer Res Treat. 2008;40:155–63.CrossRefPubMedPubMedCentral
5.
Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005;23(6):1118–24.CrossRefPubMed
6.
Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer. 2005;103(1):22–31.CrossRefPubMed
7.
Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther. 2014;7:457–67.PubMedPubMedCentral
8.
Lu R, Ji Z, Li X, Zhai Q, Zhao C, Jiang Z, et al. MiR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol. 2014;140(3):387–97.CrossRefPubMed
9.
10.
Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5(5):396–400.CrossRefPubMed
11.
Zhang F, Li Y, Zhou Q. Advances in the relationship between microRNA and cisplatin resistance of lung cancer. Zhongguo Fei Ai Za Zhi. 2014;17(3):269–72.PubMed
12.
Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.CrossRefPubMed
13.
Liu N, Jiang N, Guo R, Jiang W, He QM, Xu YF, et al. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer. 2013;12(1):123.CrossRefPubMedPubMedCentral
14.
Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW, et al. MiR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 2010;391(1):535–41.CrossRefPubMed
15.
Zhang ZC, Li YY, Wang HY, Fu S, Wang XP, Zeng MS, et al. Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma. PLoS One. 2014;9(1):e86149.CrossRefPubMedPubMedCentral
16.
Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, et al. MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 2013;329(2):181–8.CrossRefPubMed
17.
Zhao JJ, Yang JH, Lin JH, Yao N, Zhu YH, Zheng JL, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst. 2009;25(1):13–20.CrossRefPubMed
18.
Olaru AV, Ghiaur G, Yamanaka S, et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology. 2011;54(6):2089–98.CrossRefPubMedPubMedCentral
19.
Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 2012;45(1):32–8.CrossRefPubMed
20.
Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM, et al. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res. 2011;17(24):7584–94.CrossRefPubMed
21.
Kwak SY, Yang JS, Kim BY, Bae IH, Han YH. Ionizing radiation-inducible miR-494 promotes glioma cell invasion through EGFR stabilization by targeting p190B RhoGAP. Biochim Biophys Acta. 2014;1843(3):508–16.CrossRefPubMed
22.
Tutar L, Tutar E, Tutar Y. MicroRNAs and cancer; an overview. Curr Pharm Biotechnol. 2014;15(5):430–7.CrossRefPubMed
23.
Xing YU, Yibo WU, Yang LI, Deng H, Shen Z, Xiao B, et al. MiR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma. Curr Pharm Biotechnol. 2014;15(5):503–8.CrossRef
24.
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q, Wei Q, et al. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate. 2014;74(7):756–67.CrossRefPubMed
25.
26.
Ten Hagen KG, Fritz TA, Tabak LA. All in the family: the UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 2003;13(1):1R–16R.CrossRefPubMed
27.
Li W, Ma H, Sun J. MicroRNA34a/c function as tumor suppressors in Hep-2 laryngeal carcinoma cells and may reduce GALNT7 expression. Mol Med Rep. 2014;9(4):1293–8.PubMed
28.
Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 7. Biol Chem. 2012;287(17):14301–9.CrossRef
29.
Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, et al. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene. 2011;30(49):4843–54.CrossRefPubMedPubMedCentral
30.
Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, de Vega-Saenz M, et al. MiR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011;20(1):104–18.CrossRefPubMedPubMedCentral
31.
Hua F, Sun J, Guo F, Yin S, Zhang Q, Zhang W, et al. Effect of downregulated histone deacetylase 2 expression on cell proliferation and cell cycle in cervical cancer. J BUON. 2014;19(2):497–501.PubMed
32.
Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, et al. Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis. 2014;3(5):e104.CrossRefPubMedPubMedCentral
33.
Sladeczek F, Camonis JH, Burnol AF, Le Bouffant F. The Cdk-like protein PCTAIRE-1 from mouse brain associates with p11 and 14-3-3 proteins. Mol Gen Genet. 1997;254(5):571–7.CrossRefPubMed
34.
Mokalled MH, Johnson A, Kim Y, Oh J, Olson EN. Myocardin-related transcription factors regulate the Cdk5/Pctaire1 kinase cascade to control neurite outgrowth, neuronal migration and brain development. Development. 2010;137(14):2365–74.CrossRefPubMedPubMedCentral
35.
Wang Y, Fu J, Jiang MM, Zhang XA, Cheng L, Xu XJ, et al. MiR-410 is over-expressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a direct/indirect mechanism. PLoS One. 2014;9(10):e108708.CrossRefPubMedPubMedCentral
36.
Tang HL, Wang ZY, Liu Q, Liu XP, Wu MH, Li GY. Disturbing miR-182 and miR-381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. PLoS One. 2014;9(1):e84146.CrossRefPubMedPubMedCentral
37.
Zhu C, Shao PF, Bao ML, Li P, Zhou H, Cai HZ, et al. MiR-154 inhibits prostate cancer cell proliferation by targeting CCND2. Urol Oncol. 2014;32(1):31. e9-16.CrossRefPubMed
38.
Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D, et al. MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene. 2012;31(42):4509–16.CrossRefPubMed
Metadata
Title
Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma
Authors
Hong-Fang Duan
Xiao-Qing Li
Hong-Yi Hu
Yu-Chi Li
Zhi Cai
Xue-Shuang Mei
Peng Yu
Li-Ping Nie
Wei Zhang
Zhen-Dong Yu
Guo-Hui Nie
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3356-8

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Review

Survivin splice variants and their diagnostic significance

Research Article

Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma

Commentary

Reply to: “in vivo post-contrast 1H-MRS evaluation of malignant and benign breast lesions: a meta-analysis”

Research Article

miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W

Research Article

Prognostic significance of SLC9A9 in patients with resectable esophageal squamous cell carcinoma

Research Article

MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits